SCHEMBL21241833

SCHEMBL21241833

Nc1ccc(C(=O)NCC(=O)Nc2nc(-c3cccc(-c4ccncc4)c3)cs2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 7/20 0.52
▸ ROCK2 O75116 3/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HDAC3 O15379 6/20 0.47
▸ HDAC1 Q13547 6/20 0.47
▸ HDAC2 Q92769 6/20 0.47
▸ HDAC10 Q969S8 6/20 0.47
▸ HDAC6 Q9UBN7 4/20 0.47
▸ HDAC8 Q9BY41 3/20 0.47
▸ HDAC4 P56524 2/20 0.47
▸ HDAC7 Q8WUI4 2/20 0.47
▸ HDAC11 Q96DB2 2/20 0.47
▸ HDAC9 Q9UKV0 2/20 0.47
▸ HDAC5 Q9UQL6 2/20 0.47
▸ PRKACA P17612 3/20 0.46
▸ WNT3A P56704 1/20 0.46
▸ KMT2A Q03164 1/20 0.45
▸ CLK1 P49759 1/20 0.45
▸ NCOR2 Q9Y618 1/20 0.44
▸ PARP1 P09874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241880 0.89 ROCK1 (0.54) ROCK1ROCK2LMNAHDAC3HDAC1
SCHEMBL21241985 0.88 CYP3A4 (0.56) ROCK1HDAC3HDAC1HDAC2HDAC10
SCHEMBL22971635 0.87 ROCK1 (0.56) ROCK1ROCK2HDAC3HDAC1HDAC2
SCHEMBL22290469 0.83 ROCK1 (0.47) ROCK1ROCK2LMNAPRKACAWNT3A
SCHEMBL31173146 0.81 ROCK1 (0.46) ROCK1ROCK2PRKACAWNT3APARP1
SCHEMBL22290488 0.81 ROCK1 (0.46) ROCK1ROCK2PRKACAWNT3APARP1
SCHEMBL21241972 0.80 WNT3A (0.53) ROCK1ROCK2PRKACAWNT3APARP1
SCHEMBL22971566 0.80 MPL (0.51) ROCK1ROCK2HDAC3HDAC1HDAC2
SCHEMBL22971553 0.80 ROCK1 (0.54) ROCK1ROCK2HDAC3HDAC1HDAC2
SCHEMBL22971755 0.79 ROCK1 (0.53) ROCK1ROCK2PRKACAWNT3AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 — — US disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ROCK1 4248/4885ROCK2 3927/4885LMNA 225/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ROCK1 4248/4885ROCK2 3927/4885LMNA 225/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 ROCK1 1283/4885ROCK2 2299/4885LMNA 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback